Sanofi?s insulin glargine delays progression from pre-diabetes to T2DM

[Northerner]

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus? (insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer. Furthermore, the study findings, which are also published online in the New England Journal of Medicine (NEJM), showed that insulin glargine delayed progression from pre-diabetes to Type 2 diabetes (T2DM).

http://www.news-medical.net/news/20...ys-progression-from-pre-diabetes-to-T2DM.aspx